RSSDI Repository, Complications of Diabetes Demonstration RSSDI Repository, Complications of Diabetes Demonstration

Have a Question?

If you have any question you can ask below or enter what you are looking for!

  • Home/
  • Article /
  • The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy.

The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy.

Add to Collection
2010 Jun 25 Others Fist_Author_Year_PM

Full Author : ['Arora, Mandeep Kumar', 'Reddy, Krishna', 'Balakumar, Pitchai']
Journal Title : European journal of pharmacology
Chapter : Section3
Journal Year : 2010
Cited by : Not Available

The present study investigated the combined effect of low doses of fenofibrate (PPAR-alpha agonist) and rosiglitazone (PPAR-gamma agonist) in diabetes-induced experimental nephropathy. Rats were administered streptozotocin (55 mg/kg i.p., once) to induce .....

Keywords : ["low dose combination", "diabetesinduced experimental nephropathy", "rosiglitazone halt", "progression", "fenofibrate"]